01190nam0 22003011i 450 SUN001982120150916110844.27801-318-6545-520040714d1995 |0engc50 baengUS|||| |||||Physical chemistryprinciples and applications in biological sciencesIgnacio Tinoco jr., Kenneth Sauer, James C. Wang3. edEnglewood CliffsPrentice Hallc1995XIV, 761 p.ill.25 cm.Englewood CliffsSUNL000086541Chimica fisica22Tinoco, Ignacio jrSUNV016016522797Sauer, KennethSUNV016017729121Wang, James C.SUNV016018729120Prentice HallSUNV004161650Wang, J. C.Wang, James C.SUNV102635ITSOL20200706RICASUN0019821UFFICIO DI BIBLIOTECA DEL DIPARTIMENTO DI SCIENZE E TECNOLOGIE AMBIENTALI BIOLOGICHE E FARMACEUTICHE17CONS Cd10 17FMF3779 20040714 Physical chemistry1427871UNICAMPANIA11272nam 2200601 450 991049524310332120230630093617.03-030-71697-X(CKB)4100000011982808(MiAaPQ)EBC6680399(Au-PeEL)EBL6680399(OCoLC)1261365499(PPN)26030350X(EXLCZ)99410000001198280820220331d2021 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierIdentification of biomarkers, new treatments, and vaccines for COVID-19 /Paul C. Guest, editorCham, Switzerland :Springer,[2021]©20211 online resource (229 pages)Advances in experimental medicine and biology ;13273-030-71696-1 Intro -- Preface -- Contents -- Part I: Background -- 1: Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement -- 1 Introduction -- 2 Epidemiology -- 3 Main Coronavirus Groups -- 4 Genome, Genotype, and Protein Structure -- 5 Mechanism of Infection -- 6 COVID-19 Pathogenesis -- 7 Respiratory Manifestations -- 8 Extra-pulmonary Presentations -- 8.1 Gastrointestinal Manifestations -- 8.2 Cardiovascular Complications -- 8.3 Haematological Disorders -- 9 Immune Responses -- 10 Therapy -- 10.1 Drugs that Slow Viral Replication or Kill SARS-Cov-2 -- 10.2 Vaccination -- 11 Conclusion -- References -- Part II: Epidemiology -- 2: Prevalence of COVID-19 and the Continued Citizen-Based Control in Japan -- 1 Introduction -- 2 Cruise Ship Outbreak and the Environmental Assessment -- 2.1 COVID-19 Outbreak on the Diamond Princess Cruise Ship -- 2.2 Age-Related CFR Estimated from the Cruise Ship Outbreak -- 2.3 Environmental Assessment of SARS-CoV-2 on the Cruise Ship -- 3 Government-Recommended and Voluntary Measures to Protect Against COVID-19 Infection in Japan -- 4 Detection of the Coronavirus in Laboratories in Japan -- 5 Conclusions -- References -- 3: COVID-19 Pandemic in Brazil: History, Characteristics, and Evolution -- 1 Brief Historical Facts of the COVID-19 Pandemic in Brazil -- 2 Governmental Measures to Combat the Pandemic -- 3 Regional Characteristics Influencing the COVID-19 Dissemination -- 4 Prevalence of the Disease in Different Subpopulations -- 5 Concluding Remarks -- References -- 4: The Experiences of Recovered COVID-19 Patients in Baqiyatallah Hospital: A Qualitative Study -- 1 Introduction -- 2 Methods -- 2.1 Data Collection -- 2.2 Data Analysis -- 3 Results -- 3.1 Theme I: Emotional-Sensational-Paradox -- Satisfaction-Dissatisfaction -- Positive Experiences-Negative Experiences.Relaxation-Stress -- Support-Rejection -- 3.2 Theme II: Spiritual Growth -- Accepting and Submitting to Divine Providence -- Rethinking Material Possessions -- Seeking Stronger Divine Connection -- Tendency to Spirituality -- 3.3 Theme III: Experienced Mental-Psychological Effects -- Unpleasant Thoughts -- Perceived Mental Stress -- Positive Thoughts -- 4 Discussion -- 5 Conclusions -- References -- Part III: Risk Factors and Outcomes -- 5: Age-Specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons -- 1 Introduction -- 2 Age-Related Effects of Different Infections -- 3 Age Effects of COVID-19 Disease -- 4 Clinical Features in Children -- 5 The Different Etiology and Severity of COVID-19 Based on Age -- 6 Underlying Conditions and Severity of COVID-19 in Children -- 7 Outdoor Activities and the Potential to Contract the Virus -- 8 Immune System and Age-Related Differences -- 9 Innate Immune Cells and Age-Related Differences -- 10 IFN-γ and SARS-CoV in Children -- 11 Adaptive Immune Response and Age-Related Difference -- 12 Cross-Protection Against SARS-CoV-2 and Age-Related Differences -- 13 Improved Efferocytosis by Bacillus Calmette-Guerin (BCG) Vaccine to Protect Against COVID-19 Pneumonia -- 14 Age-Related Difference and Higher Hemoglobin in COVID-19 Pneumonia -- 15 The Role of Sex Hormones and Age-Related Differences in COVID-19 -- 16 Interferon as a Target Therapy in Coronavirus Disease 2019 (COVID-19) -- 17 The Role of Lactoferrin in Immune System Age-Related Differences -- 18 The Recommendations for Selecting Treatment in Patients Based on Age and Neutrophil-to-Lymphocyte Ratio (NLR) -- 19 Conclusions -- References -- 6: Sex Differences and COVID-19 -- 1 Introduction -- 1.1 COVID-19 -- 1.2 Sex and the COVID-19 Response.2 Physiological Sex Differences as Potential Moderators of COVID-19 Outcomes -- 2.1 The Immune System and COVID-19 -- 2.2 Sex Differences in the Immune System -- 2.3 Sex Hormones and the Immune Response -- 2.4 Sex Hormones and COVID-19 -- 2.5 Sex Chromosomes and the Immune System -- 2.6 Ageing, Sex and the Immune System -- 3 Sex Differences in the Renin-Angiotensin-Aldosterone System -- 3.1 Sex Differences in the Renin-Angiotensin System and COVID-19 -- 4 Reproduction, Pregnancy and COVID-19 -- 5 Long-Term Outcomes of COVID-19 and Sex Differences -- 6 Conclusion and Perspectives -- References -- 7: Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? -- 1 Introduction -- 1.1 Epidemiological Characteristics of Coronavirus Diseases -- 1.2 Coronavirus Disease 2019 (COVID-19) -- 2 Microbiota and Respiratory Infection -- 3 Potential Connections Between Intestinal Microbiota and COVID-19 -- 3.1 Age Effects -- 3.2 Hypertension -- 3.3 Diabetes -- 3.4 Obesity -- 4 COVID-19 and Microbiota -- 5 Conclusions and Future Perspectives -- References -- 8: SARS-CoV-2 Infection and the Kidneys: An Evolving Picture -- 1 Introduction -- 2 Dialysis -- 3 Transplant -- 4 Chronic Kidney Disease -- 5 Apo L1 -- 6 The Clinical Picture of Kidney Disease in COVID-19 -- 6.1 Acute Kidney Injury Pathophysiology -- 7 Conclusions -- References -- 9: Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information -- 1 Introduction -- 2 Exanthem Pattern -- 2.1 Vesicular Eruptions or Varicella-Like Exanthem -- 2.2 Maculopapular Eruptions or Maculopapular Rash -- 3 Urticarial Lesions -- 4 Vascular Pattern -- 4.1 Acral Areas of Erythema with Vesicles or Pustules (Pseudo-Chilblain) -- 4.2 Purpuric/Petechial Lesions -- 4.3 Livedo or Necrosis -- 5 Acro-Papular Eruption -- 6 Treatment -- 7 Pathophysiological Mechanisms.8 Conclusions -- References -- 10: How Do We Manage Breastfeeding During the COVID-19 Pandemic? -- 1 Introduction -- 2 Benefits of Breastfeeding -- 3 COVID-19 and Breastfeeding: Current Evidence -- 4 Guidelines on Breastfeeding for Mothers with Suspected or Confirmed COVID-19 -- 5 Conditions Recommended for Starting and Maintaining Breastfeeding -- 6 Conditions in Which It Is Recommended to Extract Breast Milk -- 7 Conditions in Which Recommended for Not Breastfeeding or Extracting Breast Milk -- 8 Breastfeeding by Mothers Undergoing Medications for COVID-19 -- 9 Conclusions and Future Perspectives -- References -- 11: Deep Learning Analysis in Prediction of COVID-19 Infection Status Using Chest CT Scan Features -- 1 Introduction -- 2 Methods -- 2.1 Study Design and Participants -- 2.2 CT Examination and Image Analysis -- 2.3 Statistical Analysis -- Comparisons Between Two Groups -- Deep Learning Analyzing and Classification -- 3 Results -- 3.1 Demographic Characteristics and Chest CT Findings -- 3.2 Deep Learning Analyzing Results -- 4 Discussion -- 5 Conclusions -- References -- Part IV: Treatments and Vaccines -- 12: Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review -- 1 Introduction -- 2 Methods -- 2.1 Inclusion Criteria -- 2.2 Search Strategy -- 3 Results -- 3.1 Extraction of Results -- 3.2 Protocols -- 3.3 Mechanism of Ozone as a Treatment -- 3.4 Ozone Therapy and Viral Infections -- 3.5 Ozone Therapy and Respiratory System -- Asthma -- Chronic Obstructive Pulmonary Disease (COPD) -- Pulmonary Emphysema -- 4 Discussion -- 5 Conclusions and Future Perspective -- References -- 13: COVID-19, Coenzyme Q10 and Selenium -- 1 Introduction -- 2 CoQ10 -- 3 Selenium -- 4 Oxidative Stress, Inflammation and Virus Infection -- 4.1 Oxidative Stress -- 4.2 Inflammation.5 Supplementation CoQ10 and Selenium -- 6 Conclusions and Future Perspectives -- References -- 14: Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19) -- 1 Introduction -- 2 Agents with Known Effect Against SARS-CoV-2 -- 2.1 Alcohol and Isopropanol -- 2.2 Povidone-Iodine -- 2.3 Hydrogen Peroxide -- 2.4 Ultraviolet (UV) Radiation -- 2.5 Xylitol -- 2.6 Brilacidin -- 2.7 Carrageenan -- 3 Agents with Potential Effect on SARS-CoV-2 -- 3.1 Acid-Buffered Saline -- 3.2 Hypertonic Saline -- 3.3 Oxymetazoline and Xylometazoline -- 3.4 Probiotics -- 3.5 Chlorhexidine -- 3.6 Citrox (Flavonoids) and Cyclodextrins -- 3.7 Cetylpyridinium Chloride (CPC) -- 3.8 Surfactants/Shampoo -- 3.9 Interferon -- 4 Therapeutic Application and Method of Delivery -- 5 Conclusions -- References -- 15: Cinnamon: A Promising Natural Product Against COVID-19 -- 1 Introduction -- 2 Antiallergic Properties -- 3 Antiviral Properties -- 4 Cardiovascular Properties -- 5 Safety of Cinnamon -- 6 Conclusions and Future Perspectives -- References -- 16: Curcumin and Piperine in COVID-19: A Promising Duo to the Rescue? -- 1 Introduction -- 2 Curcumin-Piperine -- 3 Curcumin-Piperine and Virus-Induced Lung Injury -- 4 Curcumin-Piperine and Thrombosis -- 5 Safety of Curcumin-Piperine -- 6 Conclusions and Future Perspectives -- References -- 17: Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19 -- 1 Introduction -- 2 Methods -- 2.1 Study Design and Participants -- 2.2 Data Collection -- 2.3 Medication -- 2.4 Outcomes -- 2.5 Statistical Analysis -- 3 Results -- 4 Discussion -- 5 Conclusion -- References -- 18: The Worldwide Effort to Develop Vaccines for COVID-19 -- 1 Introduction -- 2 The SARS-CoV-2 Spike Protein.3 SARS-CoV-2 Vaccine Candidates in Phase 3 Clinical Trials.Advances in experimental medicine and biology ;1327.COVID-19 (Disease)COVID-19thubMarcadors bioquímicsthubTerapèuticathubVacunesthubLlibres electrònicsthubCOVID-19 (Disease)COVID-19Marcadors bioquímicsTerapèuticaVacunes614.592414Guest Paul C.MiAaPQMiAaPQMiAaPQBOOK9910495243103321Identification of biomarkers, new treatments, and vaccines for COVID-192818630UNINA